Elena Peletskaya
About Elena Peletskaya
Elena Peletskaya is the Sr. Director of Portfolio Technical Strategy at Bristol Myers Squibb, with extensive experience in gene therapy, regulatory strategy, and assay development.
Current Role at Bristol Myers Squibb
Elena Peletskaya currently holds the position of Sr. Director, Portfolio Technical Strategy at Bristol Myers Squibb. Based in Seattle, Washington, she leads the development of gene delivery analytics strategies and plays a crucial role in regulatory strategy and submissions for cell and gene therapy products. Her work in analytical development of viral vectors and gene editing technologies is instrumental in advancing the company's portfolio.
Previous Experience at Juno Therapeutics, Celgene, Bristol Myers Squibb
Before her current role, Elena Peletskaya served as Director at Juno Therapeutics, Celgene, and Bristol Myers Squibb, all located in Seattle, Washington. In these positions, she contributed significantly to the analytical development and regulatory strategies of cell and gene therapy products. Her extensive experience in this field has helped in the advancement and innovation of therapeutic solutions.
Role at DiaCarta Inc.
From 2015 to 2018, Elena Peletskaya worked as Director, IVD at DiaCarta Inc. in Hayward, CA. There, she honed her skills in clinical and IVD assay development, leading initiatives that contributed to significant advancements in the field. Her work focused on ensuring the quality and efficacy of various diagnostic tools and technologies.
Academic Background and Research Positions
Elena Peletskaya achieved her M.Sc. in Physiology and B.Sc. in Biology from Moscow State University. She also holds a Ph.D. in Molecular Virology and Medical Sciences from the National Institute Of Virology. Her academic journey laid the foundation for her extensive research career, including roles as Research Assistant Professor at the University of Vermont and the University of Missouri, Principal Scientist at Biolinx, LLC, and Guest Scientist at the National Cancer Institute.
Contributions to Cell and Gene Therapy
Throughout her career, Elena Peletskaya has made significant contributions to the advancement of cell and gene therapy. Her leadership roles have involved the development and implementation of analytical methods for viral vectors and gene editing technologies. Her experience spans from her early days at the National Cancer Institute to her recent work at major biopharmaceutical companies, making her a pivotal figure in the field.